Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

NCT05564936 · View on ClinicalTrials.gov ↗

Study Summary

ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.

Conditions Studied

Interventions

  • DEVICE ME&MG mobile application

Study Locations (19)

Other

  • Hôpital Raymond Poincaré — Garches
  • CHU Grenoble — Grenoble
  • Hôpital Salengro — Lille
  • CHRU Nancy — Nancy
  • CHU Nantes — Nantes
  • Pitié-Salpêtrière — Paris
  • CHU de Strasbourg - Hôpital de Hautepierre — Strasbourg
  • CHU Toulouse — Toulouse

Indiana

  • HealthParterns Institute — Bloomington
  • Indiana University Health — Indianapolis

Tennessee

  • The University of Tennessee Medical Center — Knoxville
  • Vanderbilt Health — Nashville

Colorado

  • University of Colorado Denver — Aurora

Florida

  • University of Florida Health — Jacksonville

Kentucky

  • University of Kentucky — Lexington

New York

  • Neurological Associates of Long Island, P.C. — Lake Success

North Carolina

  • Duke University — Durham

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-01-24
Est. Completion 2026-09-24
Phase NA

Sponsor

Ad scientiam

35 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05564936

The ClinicalTrials.gov registry entry for NCT05564936 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ad scientiam, which has 35 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention — of which ME&MG mobile application is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05564936 reports 19 study locations spanning 10 distinct geographic areas — top geographies include Other, Indiana, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05564936 about?

NCT05564936 is a clinical study titled "The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis". ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests...

What is the current status of trial NCT05564936?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2024-01-24. Estimated completion is 2026-09-24.

What conditions does trial NCT05564936 study?

This clinical trial studies the following conditions: Myasthenia Gravis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05564936?

The interventions under investigation include: ME&MG mobile application (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05564936?

This trial is sponsored by Ad scientiam, which has 35 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05564936 being conducted?

This trial has 19 study locations across Colorado, Florida, Indiana, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial